| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10105335 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US9326947 | BANNER LIFE SCIENCES | Controlled release fumarate esters |
Feb, 2035
(10 years from now) | |
| US9517209 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US9566259 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US10105337 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US9820960 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US9636319 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US10098863 | BANNER LIFE SCIENCES | Fumarate esters |
Feb, 2035
(10 years from now) | |
| US9326965 | BANNER LIFE SCIENCES | Controlled release fumarate esters |
Feb, 2035
(10 years from now) | |
| US9814692 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US9636318 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US9814691 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US9511043 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US10105336 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Feb, 2035
(10 years from now) | |
| US9820961 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Feb, 2035
(10 years from now) | |
| US10918616 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Jun, 2035
(11 years from now) | |
| US10918617 | BANNER LIFE SCIENCES | Fumarate ester pharmaceutical compositions |
Aug, 2035
(11 years from now) | |
| US10918615 | BANNER LIFE SCIENCES | Fumarate esters |
Aug, 2035
(11 years from now) | |
| US10945985 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Aug, 2035
(11 years from now) | |
| US11590095 | BANNER LIFE SCIENCES | Fumarate ester dosage forms |
Mar, 2036
(11 years from now) | |
Bafiertam is owned by Banner Life Sciences.
Bafiertam contains Monomethyl Fumarate.
Bafiertam has a total of 20 drug patents out of which 0 drug patents have expired.
Bafiertam was authorised for market use on 28 April, 2020.
Bafiertam is available in capsule, delayed release;oral dosage forms.
Bafiertam can be used as method of treating multiple sclerosis.
The generics of Bafiertam are possible to be released after 18 March, 2036.
Drugs and Companies using MONOMETHYL FUMARATE ingredient
Market Authorisation Date: 28 April, 2020
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
BAFIERTAM family patents
